濮阳东方医院割包皮手术便宜吗(濮阳东方医院做人流评价很高) (今日更新中)

SAN FRANCISCO, Nov. 7 (Xinhua) -- Google on Monday added a highly-anticipated service to its Google+ social network, allowing businesses and brands to set up their own pages on the site.Named "Google+ Page," the service is a further challenge to its rival Facebook's fan pages, which has become a major promotion strategy for many business brands over the past several years.Unlike Facebook, Google will not charge businesses and organizations for using the scheme, and will not put ads on the pages. The service is expected to enhance the tech giant's other businesses like search and mobile advertising.Some big brand names, such as Burberry, the Barcelona football club and the Muppets, have already set up their pages.Google noted it will not pass on personal data.In addition to big brands, Google also wants small businesses that have or do not have their own websites to use Google+ Pages as their default presences.According to a report by Ad Age Digital, Google+ Pages will soon be location-aware, allowing local businesses to send offers and deals to mobile phones.According to Google, more than 40 million people have opened an account with its social network, which was launched in June. Although the network is growing very quickly, some analysts said it still has a long way to go to become a major threat to Facebook, which has more than 800 million users.

BEIJING, Oct. 12(Xinhuanet) -- People allergic to peanuts may find relief in a new research by American scientists, according to Huffington Post Monday.Scientists from the Northwestern University Feinberg School of Medicine have found a way to turn off allergic responses by creating an immune system tolerant to peanuts.They attached peanut proteins, the source of the allergy, to white blood cells of mice. Then the mice's immune systems would recognise the proteins and become tolerant to them.When people eat peanuts, allergic human bodies would recognize peanut proteins as invading pathogens and trigger immune responses like throat swelling, even closing up, which can be lethal. Ditto for mice's bodies.But when peanut protein attached to the body's own cells, the immune systems would regard the peanut proteins as perfectly normal and not attack the cells, said Paul Bryce, an assistant professor involved in the study. Then the allergic responses disappeared.The research was conducted on mice. But the scientists expected the method to cure peanut allergies could apply to humans, according to Huffington Post.Although the research was promising, it did not mean that peanut allergies in humans could be actually cured in the foreseeable future, said Dr. Clifford Basset medical director at Allergy and Asthma Care of New York, to ABC News, "Its all about education, prevention and preparedness".

BEIJING, Nov. 10 (Xinhuanet) -- Awareness in three vegetative patients were detected in a portable electrode test, a new study shows. If replicated, the method may change standards in treating such patients.The new study, published online in the journal The Lancet Wednesday, was reported to be the first to detect signs of awareness in patients living in the unresponsive state through more accessible electroencephalogram (EEG) machine.The EEG is a portable and more affordable technique than Magnetic Resonance Imaging (MRI) scanner, but it is as effective as the MRI to diagnose patients in the vegetative state, according to the research team led by Damian Cruse and Adrian M. Owen of the University of Western Ontario.In the research test, the team hooked 16 previously determined to be vegetative patients to EEG machines and gave simple instructions to them like moving their fingers and toes.The machines show that the patterns in the premotor cortex, the area of the brain that plans and prepares movements, in three of 16 patients were exactly the same as those of healthy volunteers.While the patients were able to follow simple instructions, they were not able to make their own decisions about their state, the researchers said.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

SHANGHAI, Jan. 11 (Xinhua) -- The listed arm of China's biggest train maker, China South Locomotive and Rolling Stock Industry (Group) Corporation (CSR), has been allowed by regulatory authorities to raise 9 billion yuan (1.41 billion U.S. dollars) on the stock market, the company said Wednesday.The Hong Kong- and Shanghai- listed CSR Corp. Ltd. will sell 1.96 billion shares at 4.46 yuan apiece to select investors, it said. But CSR's parent -- state-owned CSR Group -- has agreed to buy no less than 6 billion yuan's worth of the shares, leaving the rest to institutional investors.CSR's net profit growth in the third quarter of 2011 plunged to 9.66 percent year-on-year from a high of 85.08 percent in the first half of 2011 as the country put the brakes on development of the railway sector after a deadly bullet train crash on July 23 that killed 40 people and injured 210 others.The decision to slow the development of high-speed rail lines has led to halts in construction of about 90 percent of ongoing railway projects, or 10,000 km of rail lines across the country, local media reported earlier.CSR is the maker of the bullet trains involved in last July's deadly collision. After the accident, the company's executives bought a combined 540,000 share in August, a move seen as an attempt to bolster battered stock prices.Analysts say the fundraising would help CSR greatly ease its financial burdens. The company earlier pledged to maintain profit growth and its dividend policy to boost investors' confidence.

来源：资阳报